CRISPR Therapeutics AG vs ImmunityBio, Inc.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: CRISPR Therapeutics AG and ImmunityBio, Inc., from 2014 to 2023.

CRISPR Therapeutics AG, known for its groundbreaking work in gene editing, saw its SG&A expenses grow by approximately 1,400% from 2014 to 2021, peaking in 2021. However, a notable decline of around 26% was observed in 2023, reflecting strategic cost management or shifts in operational focus.

Conversely, ImmunityBio, Inc., a leader in immunotherapy, experienced a dramatic spike in 2015, with expenses surging by over 5,000% compared to the previous year. Despite fluctuations, their expenses remained relatively high, indicating sustained investment in growth and development.

These trends highlight the contrasting financial strategies of these biotech giants, offering valuable insights into their operational priorities and market positioning.